Steph & Co. trimmed its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 23.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,578 shares of the biopharmaceutical company’s stock after selling 2,571 shares during the quarter. Steph & Co.’s holdings in Bristol-Myers Squibb were worth $440,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently made changes to their positions in the stock. Herold Advisors Inc. lifted its holdings in Bristol-Myers Squibb by 3.2% in the 3rd quarter. Herold Advisors Inc. now owns 33,668 shares of the biopharmaceutical company’s stock valued at $1,954,000 after acquiring an additional 1,051 shares during the last quarter. Kestra Private Wealth Services LLC grew its stake in shares of Bristol-Myers Squibb by 9.5% in the 3rd quarter. Kestra Private Wealth Services LLC now owns 139,811 shares of the biopharmaceutical company’s stock worth $8,115,000 after purchasing an additional 12,121 shares during the last quarter. Metis Global Partners LLC raised its holdings in shares of Bristol-Myers Squibb by 14.8% in the 3rd quarter. Metis Global Partners LLC now owns 101,772 shares of the biopharmaceutical company’s stock worth $5,907,000 after purchasing an additional 13,122 shares in the last quarter. Jmac Enterprises LLC lifted its stake in Bristol-Myers Squibb by 11.4% during the third quarter. Jmac Enterprises LLC now owns 12,171 shares of the biopharmaceutical company’s stock valued at $706,000 after purchasing an additional 1,245 shares during the last quarter. Finally, Signaturefd LLC boosted its holdings in Bristol-Myers Squibb by 0.5% during the third quarter. Signaturefd LLC now owns 105,986 shares of the biopharmaceutical company’s stock worth $6,151,000 after buying an additional 564 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.
Bristol-Myers Squibb Stock Down 0.9 %
BMY stock traded down $0.42 during mid-day trading on Wednesday, hitting $47.84. The stock had a trading volume of 11,723,377 shares, compared to its average volume of 15,847,039. The stock has a market capitalization of $96.96 billion, a price-to-earnings ratio of 12.50, a PEG ratio of 1.46 and a beta of 0.39. The company has a fifty day moving average of $51.27 and a 200 day moving average of $51.62. Bristol-Myers Squibb has a 1-year low of $47.58 and a 1-year high of $70.93. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 1.24.
Bristol-Myers Squibb Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be issued a dividend of $0.60 per share. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 annualized dividend and a yield of 5.02%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 62.18%.
Wall Street Analyst Weigh In
Several research analysts have issued reports on BMY shares. Wells Fargo & Company dropped their price target on Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 6th. StockNews.com downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Bank of America downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $68.00 to $60.00 in a report on Wednesday, January 3rd. Finally, William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $61.12.
Get Our Latest Stock Analysis on Bristol-Myers Squibb
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Featured Stories
- Five stocks we like better than Bristol-Myers Squibb
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- United Airlines Soars on Earnings Beat
- Trading Stocks: RSI and Why it’s Useful
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Stock Market Sectors: What Are They and How Many Are There?
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.